JP2022519764A5 - - Google Patents

Info

Publication number
JP2022519764A5
JP2022519764A5 JP2021547374A JP2021547374A JP2022519764A5 JP 2022519764 A5 JP2022519764 A5 JP 2022519764A5 JP 2021547374 A JP2021547374 A JP 2021547374A JP 2021547374 A JP2021547374 A JP 2021547374A JP 2022519764 A5 JP2022519764 A5 JP 2022519764A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017974 external-priority patent/WO2020167984A1/en
Publication of JP2022519764A publication Critical patent/JP2022519764A/ja
Publication of JP2022519764A5 publication Critical patent/JP2022519764A5/ja
Pending legal-status Critical Current

Links

JP2021547374A 2019-02-14 2020-02-12 二環式スルホンアミド Pending JP2022519764A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805725P 2019-02-14 2019-02-14
US62/805,725 2019-02-14
PCT/US2020/017974 WO2020167984A1 (en) 2019-02-14 2020-02-12 Bicyclic sulfonamides

Publications (2)

Publication Number Publication Date
JP2022519764A JP2022519764A (ja) 2022-03-24
JP2022519764A5 true JP2022519764A5 (https=) 2023-02-21

Family

ID=72045615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547374A Pending JP2022519764A (ja) 2019-02-14 2020-02-12 二環式スルホンアミド

Country Status (13)

Country Link
US (1) US11033556B2 (https=)
EP (1) EP3924357A4 (https=)
JP (1) JP2022519764A (https=)
KR (1) KR20210126636A (https=)
CN (1) CN113423712A (https=)
AU (1) AU2020221839B2 (https=)
BR (1) BR112021015864A2 (https=)
CA (1) CA3128061A1 (https=)
IL (1) IL284940A (https=)
MX (1) MX2021009717A (https=)
SG (1) SG11202108835SA (https=)
TW (1) TW202045516A (https=)
WO (1) WO2020167984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
EP4399217A2 (en) 2021-09-08 2024-07-17 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108264520B (zh) 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Similar Documents

Publication Publication Date Title
JP2022519764A5 (https=)
JP2021534124A5 (https=)
JP2018531919A (ja) B型肝炎ウイルスコアタンパク質モジュレーター
KR970705393A (ko) 암 치료를 위한 화합물 및 방법(compounds and methods for the treatment of cancer)
JP2016534148A5 (https=)
JP2011509309A5 (https=)
JP2020521740A5 (https=)
JP2022505597A5 (https=)
JP2020515610A5 (https=)
JP2015526448A5 (https=)
JP2017518959A5 (https=)
JP2017528498A5 (https=)
JP2022505841A5 (https=)
RU97105381A (ru) Соединения и способы для лечения рака
JP2022522312A5 (https=)
JP2017526726A5 (https=)
JP2008535903A5 (https=)
JP2020507589A5 (https=)
JP2006507355A5 (https=)
JP7648528B2 (ja) モノマーおよびマルチマー抗hbv薬
JP2023513797A5 (https=)
JP2022505989A5 (https=)
JP2022529466A5 (https=)
US20210251991A1 (en) Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
JP2011509302A5 (https=)